Results 21 to 30 of about 174,614 (242)

Low-Dose Continuous 5-Fluorouracil Combined with Leucovorin, nab-Paclitaxel, Oxaliplatin, and Bevacizumab for Patients with Advanced Pancreatic Cancer: A Retrospective Analysis. [PDF]

, 2018
BackgroundContinuous-infusion 5-fluorouracil (5FU) and calcium leucovorin plus nab-paclitaxel and oxaliplatin have been shown to be active in patients with pancreatic cancer.
Bedford, Rudolph, Donahue, Timothy, Hines, O Joe, Hoos, William, Isacoff, William H, Rahib, Lola, Reber, Howard A, Upfill-Brown, Alexander   +7 more
core   +1 more source

European medicines agency approval summary: zaltrap for the treatment of patients with oxaliplatin-resistant metastatic colorectal cancer [PDF]

, 2017
On 1 February 2013, a marketing authorisation valid throughout the European Union was issued for aflibercept (Zaltrap) in combination with irinotecan/5-fluorouracil/ folinic acid chemotherapy for the treatment of adults with metastatic colorectal cancer ...
Caleno, Mariapaola, Foggi, Paolo, Gravanis, Iordanis, Melchiorri, Daniela, Pignatti, Francesco, Salmonson, Tomas, Sjöberg, Jan, Stanel, Stefan Cristian, Tzogani, Kyriaki   +8 more
core   +1 more source

A phase II study of capecitabine and oxalplatin combination chemotherapy in patients with inoperable adenocarcinoma of the gall bladder or biliary tract [PDF]

, 2016
Background: Advanced biliary tract carcinomas are associated with a poor prognosis, and palliative chemotherapy has only modest benefit. This multi-centre phase II study was conducted to determine the efficacy of capecitabine in combination with ...
E. Soulis, F. Y. Coxon, J. S. Graham, K. Boyd, L. R. Wall, M. Highley, M. M. Eatock, P. Bützberger-Zimmerli, S. Harden, T. R. J. Evans, T. S. Maughan   +10 more
core   +1 more source

High incidence of Angina pectoris in patients treated with 5-fluorouracil - A planned surveillance study with 102 patients [PDF]

, 2003
Objective: Angina pectoris, arrhythmic sudden death and myocardial infarction, all these cardiac events have occasionally been reported during 5-fluorouracil (5-FU) chemotherapy.
Lersch, C., Reindl, L., Scherpinski, U., Seyfarth, M., Wacker, A.   +4 more
core   +1 more source

Capecitabine as second-line treatment for metastatic cholangiocarcinoma: A report of two cases [PDF]

, 2002
Background: The management of recurrent, metastatic cholangiocarcinoma still remains a problem since this tumor entity is classified as chemotherapy-resistant.
Heinemann, Volker, Schalhorn, A., Stemmler, Joachim   +2 more
core   +1 more source

Laryngeal Preservation Strategies in Locally Advanced Laryngeal and Hypopharyngeal Cancers. [PDF]

, 2019
For long, the treatment of locoregionally advanced laryngeal and hypopharyngeal squamous cell cancers (SCC) consisted of either total laryngectomy (TL) or definitive radiotherapy (RT).
Argiris, Athanassios, Lefebvre, Jean Louis   +1 more
core   +2 more sources

Detecting homologous recombination deficiency for breast cancer through integrative analysis of genomic data

Molecular Oncology, EarlyView.
This study develops a semi‐supervised classifier integrating multi‐genomic data (1404 training/5893 validation samples) to improve homologous recombination deficiency (HRD) detection in breast cancer. Our method demonstrates prognostic value and predicts chemotherapy/PARP inhibitor sensitivity in HRD+ tumours.
Rong Zhu, Katherine Eason, Suet‐Feung Chin, Paul A. W. Edwards, Raquel Manzano Garcia, Richard Moulange, Jia Wern Pan, Soo Hwang Teo, Sach Mukherjee, Maurizio Callari, Carlos Caldas, Stephen‐John Sammut, Oscar M. Rueda   +12 more
wiley   +1 more source

TRPM8 levels determine tumor vulnerability to channel agonists

Molecular Oncology, EarlyView.
TRPM8 is a Ca2+ permissive channel. Regardless of the amount of its transcript, high levels of TRPM8 protein mark different tumors, including prostate, breast, colorectal, and lung carcinomas. Targeting TRPM8 with channel agonists stimulates inward calcium currents followed by emptying of cytosolic Ca2+ stores in cancer cells.
Alessandro Alaimo, Francesco Giuseppe Carbone, Kristi Buzo, Nicole Annesi, Sacha Genovesi, Annalisa Lorenzato, Karen Widmann, Michela Libergoli, Elisa Marmocchi, Giovanni Bertalot, Alberto Brolese, Mauro Giulio Papotti, Luca Molinaro, Orazio Caffo, Mattia Barbareschi, Alberto Bardelli, Alessandro Romanel, Sabrina Arena, Andrea Lunardi   +18 more
wiley   +1 more source

Anti epidermal growth factor receptor therapy in small bowel adenocarcinoma [PDF]

, 2018
Rationale:Small bowel adenocarcinoma (SBA) is an uncommon gastrointestinal cancer, thus limited data about treatment for advanced disease are available.
Anselmi, Elisabetta, Falcone, Rosa, Filetti, Marco, Marchetti, Paolo, Roberto, Michela   +4 more
core   +1 more source

The subcellular distribution of phosphorylated Y‐box‐binding protein‐1 at S102 in colorectal cancer patients, stratified by KRAS mutational status and clinicopathological features

Molecular Oncology, EarlyView.
This study identifies nuclear YB‐1 S102 phosphorylation as a marker associated with KRAS and FBXW7 mutations in colorectal cancer. Mutated KRAS correlates specifically with nuclear, not cytoplasmic, S102 YB‐1. These findings provide the first ex vivo evidence of this link in CRC and suggest future studies should assess the prognostic and therapeutic ...
Konstanze Lettau, Stephan Forchhammer, Birgit Fehrenbacher, Lejla Mahmutovic, Marcus Scharpf, Gunnar Blumenstock, Martin Schaller, Irina Bonzheim, Shayan Khozooei, Mahmoud Toulany   +9 more
wiley   +1 more source